Literature DB >> 23135876

Is fluorine-18-fluorodeoxyglucose positron emission tomography useful in monitoring the response to treatment in patients with multiple myeloma?

Carmelo Caldarella1, Maria Antonietta Isgrò, Ivan Treglia, Giorgio Treglia.   

Abstract

Fluorine-18-fluorodeoxyglucose positron emission tomography (FDG-PET) is a useful diagnostic tool for the staging of patients with multiple myeloma (MM). The aim of this study is to perform a systematic review of the usefulness of FDG-PET or PET/CT in monitoring response to treatment in patients with MM. A comprehensive computer literature search of the PubMed/MEDLINE, Scopus and Embase databases was carried out to identify relevant peer-reviewed articles on the use of FDG-PET or PET/CT in monitoring the response to treatment in patients with MM. Ten studies described investigations of the role of FDG-PET or PET/CT in monitoring the response to treatment in 690 patients with MM or solitary plasmacytoma: six of these were conducted prospectively, while four studies were retrospective. These articles were retrieved in full-text version and analyzed. Based on these findings from the literature, FDG-PET or PET/CT appear to be useful in the assessment of treatment response in patients with MM.

Entities:  

Mesh：

Substances：

Year:  2012        PMID： 23135876     DOI： 10.1007/s12185-012-1215-6

Source DB:  PubMed          Journal:  Int J Hematol        ISSN： 0925-5710            Impact factor:   2.490


  37 in total

1.  Value of 18F-fluorodeoxyglucose uptake in positron emission tomography/computed tomography in predicting survival in multiple myeloma.

Authors:  Rauf Haznedar; Sahika Z Akı; Ozgür U Akdemir; Zübeyde N Ozkurt; Ozcan Ceneli; Münci Yağcı; Gulsan T Sucak; Mustafa Unlü
Journal:  Eur J Nucl Med Mol Imaging       Date:  2011-02-02       Impact factor: 9.236

2.  Does multiple myeloma incidence vary by geographic area?

Authors:  Elizabeth Ann Coleman; John W Senner; Brenda K Edwards
Journal:  J Ark Med Soc       Date:  2008-10

3.  Diagnostic utility of FDG PET in multiple myeloma.

Authors:  Hossein Jadvar; Peter S Conti
Journal:  Skeletal Radiol       Date:  2002-09-26       Impact factor: 2.199

4.  The value of FDG PET/CT in the initial staging and bone marrow involvement of patients with multiple myeloma.

Authors:  Sait Sager; Nurhan Ergül; Hediye Ciftci; Güven Cetin; Sebnem Izmir Güner; Teyfik Fikret Cermik
Journal:  Skeletal Radiol       Date:  2011-01-13       Impact factor: 2.199

5.  International staging system for multiple myeloma.

Authors:  Philip R Greipp; Jesus San Miguel; Brian G M Durie; John J Crowley; Bart Barlogie; Joan Bladé; Mario Boccadoro; J Anthony Child; Herve Avet-Loiseau; Jean-Luc Harousseau; Robert A Kyle; Juan J Lahuerta; Heinz Ludwig; Gareth Morgan; Raymond Powles; Kazuyuki Shimizu; Chaim Shustik; Pieter Sonneveld; Patrizia Tosi; Ingemar Turesson; Jan Westin
Journal:  J Clin Oncol       Date:  2005-04-04       Impact factor: 44.544

Review 6.  Bone scintigraphy in common tumors with osteolytic components.

Authors:  K Wang; Li Allen; E Fung; C C Chan; J C S Chan; J F Griffith
Journal:  Clin Nucl Med       Date:  2005-10       Impact factor: 7.794

7.  Role of 18F-FDG PET/CT in the assessment of bone involvement in newly diagnosed multiple myeloma: preliminary results.

Authors:  Cristina Nanni; Elena Zamagni; Mohsen Farsad; Paolo Castellucci; Patrizia Tosi; Delia Cangini; Eugenio Salizzoni; Romeo Canini; Michele Cavo; Stefano Fanti
Journal:  Eur J Nucl Med Mol Imaging       Date:  2006-02-02       Impact factor: 9.236

8.  Cancer statistics, 1998.

Authors:  S H Landis; T Murray; S Bolden; P A Wingo
Journal:  CA Cancer J Clin       Date:  1998 Jan-Feb       Impact factor: 508.702

9.  F18-fluorodeoxyglucose positron emission tomography in the context of other imaging techniques and prognostic factors in multiple myeloma.

Authors:  Twyla B Bartel; Jeff Haessler; Tracy L Y Brown; John D Shaughnessy; Frits van Rhee; Elias Anaissie; Terri Alpe; Edgardo Angtuaco; Ronald Walker; Joshua Epstein; John Crowley; Bart Barlogie
Journal:  Blood       Date:  2009-05-14       Impact factor: 22.113

10.  Criteria for the classification of monoclonal gammopathies, multiple myeloma and related disorders: a report of the International Myeloma Working Group.

Authors: 
Journal:  Br J Haematol       Date:  2003-06       Impact factor: 6.998
View more
  6 in total

1.  Limited value of the international staging system for predicting long-term outcome of transplant-ineligible, newly diagnosed, symptomatic multiple myeloma in the era of novel agents.

Authors:  Junya Kuroda; Yuji Shimura; Kensuke Ohta; Hirokazu Tanaka; Hirohiko Shibayama; Satoru Kosugi; Shinichi Fuchida; Masayuki Kobayashi; Hitomi Kaneko; Nobuhiko Uoshima; Kazuyoshi Ishii; Shosaku Nomura; Masafumi Taniwaki; Akifumi Takaori-Kondo; Chihiro Shimazaki; Mitsuru Tsudo; Masayuki Hino; Itaru Matsumura; Yuzuru Kanakura
Journal:  Int J Hematol       Date:  2014-03-01       Impact factor: 2.490

Review 2.  Minimal residual disease analysis in myeloma - when, why and where.

Authors:  Uday Yanamandra; Shaji K Kumar
Journal:  Leuk Lymphoma       Date:  2017-10-11

3.  Solitary Plasmacytoma of the Sternum Mimicking Bone Metastasis in a Patient with a History of Breast Cancer Evaluated by F-18-FDG PET/CT.

Authors:  Giorgio Treglia; Luca Giovanella; Barbara Muoio; Carmelo Caldarella
Journal:  Nucl Med Mol Imaging       Date:  2013-12-13

Review 4.  Positron emission tomography image-guided drug delivery: current status and future perspectives.

Authors:  Rubel Chakravarty; Hao Hong; Weibo Cai
Journal:  Mol Pharm       Date:  2014-06-04       Impact factor: 4.939

5.  Correlation Between Uptake of 18F-FDG During PET/CT and Ki-67 Expression in Patients Newly Diagnosed With Multiple Myeloma Having Extramedullary Involvement.

Authors:  Qian Li; Jing Ma; Han Li; Wengui Xu; Zeng Cao; Su Liu; Lin Chen; Shuang Gao; Tinghui Yan; Dongying Li; Xue Wang; Yuanfang Yue; Zhigang Zhao; Xiaofang Wang; Hongliang Yang; Haifeng Zhao; Yong Yu; Yizhuo Zhang; Feiyue Fan; Yafei Wang
Journal:  Technol Cancer Res Treat       Date:  2019-01-01

6.  Semi-quantitative analysis of 18F fluorodeoxyglucose uptake in the assessment of disease activity and therapeutic response in rheumatoid arthritis: An institutional experience.

Authors:  Reddy Ravikanth; Jyotin Kshitiz Singh
Journal:  World J Nucl Med       Date:  2020-06-27
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.